|
Market Closed -
Nasdaq
16:00:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 8.560 USD | +6.34% |
|
+15.05% | +104.78% |
| 09-21 | Precigen Receives Fda Platform Technology Designation for Adenoverse Platform | CI |
| 09-21 | Precigen's AdenoVerse Receives FDA Platform Technology Designation | MT |
Company Valuation: Precigen, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 767 | 316.4 | 333.6 | 328 | 1,479 | 3,065 | - | - |
| Change | - | -58.75% | 5.42% | -1.66% | 350.89% | 107.22% | - | - |
| Enterprise Value (EV) | 835 | 260.3 | 270.7 | 230.1 | 1,474 | 3,065 | 3,065 | 3,065 |
| Change | - | -68.82% | 3.99% | -15% | 540.71% | 107.88% | 0% | 0% |
| P/E | -7.89x | 10.9x | -3.44x | -2.38x | -3.05x | 38.4x | 13.5x | 12.2x |
| PBR | 7.15x | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | -0.1x | -0x | -0x | 0x | 1.2x |
| Capitalization / Revenue | 7.38x | 11.8x | 53.6x | 83.6x | 153x | 12.8x | 6.91x | 5.98x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 12.8x | 6.91x | 5.98x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 29.3x | 10.4x | 10.2x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | 70x | 8.81x | 10.7x |
| FCF Yield | -8.22% | -71% | -33.5% | -23.4% | -6.07% | 1.43% | 11.4% | 9.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.47 | 0.14 | -0.39 | -0.47 | -1.37 | 0.2227 | 0.6343 | 0.6997 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 103.9 | 26.91 | 6.225 | 3.925 | 9.684 | 238.8 | 443.5 | 512.1 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -78.78 | -75.73 | -99.76 | -135 | -110.5 | 104.8 | 295.2 | 300.8 |
| Net income 1 | -92.17 | 28.32 | -95.9 | -126.2 | -429.6 | 86.06 | 245.5 | 283.6 |
| Net Debt | 67.99 | -56.07 | -62.86 | -97.91 | -4.684 | - | - | - |
| Reference price 2 | 3.710 | 1.520 | 1.340 | 1.120 | 4.180 | 8.560 | 8.560 | 8.560 |
| Nbr of stocks (in thousands) | 206,738 | 208,150 | 248,919 | 292,869 | 353,824 | 358,035 | - | - |
| Announcement Date | 3/1/22 | 3/6/23 | 3/19/24 | 3/19/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 38.43x | - | - | - | 3.06B | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 28.13x | 6.65x | 17.60x | 2.24% | 376.69B | |
| Weighted average by Cap. | 32.11x | 7.72x | 18.90x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PGEN Stock
- Valuation Precigen, Inc.
Select your edition
All financial news and data tailored to specific country editions
